LAUSANNE, Switzerland -- Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs ...

The SIB Swiss Institute of Bioinformatics, Geneva Bioinformatics (GeneBio) SA and Quartz Bio SA today announced the establishment of a long-term collaboration under which they will cooperate in order ...

Quartz Bio will offer highly specialized services to the pharmaceutical industry in the field of biomarker data analysis Merck Serono, a division of Merck, Darmstadt, Germany, announced today the ...

Merck Serono, the biopharmaceutical division of Merck KGaA ( MKGAF), announced the creation of a new company, Asceneuron. Asceneuron is the third spin-off company of Merck Serono, apart from Prexton ...

Merck Serono has created another spin-off company as part of its entrepreneurship programme, designed to provide start-up opportunities to employees affected by the closure of its Geneva headquarters.

Quartz Bio, a new company offering biomarker data management and exploratory biomarker analysis services to the pharmaceutical industry, has emerged as the second offshoot of Merck Serono’s ...

Merck Serono has spun out a bioinformatics firm, Quartz Bio, to provide biomarker data management and exploratory biomarker analysis services to the pharma industry. The new firm is the second created ...

Debiopharm Group™ has announced that they have signed a one-year collaboration agreement with Quartz Bio, the Clinical Bioinformatics Research Organization leader in precision biomarker discovery.

Merck Serono, the biopharmaceutical division of Merck KGaA (MKGAY), announced the creation of a new company, Asceneuron. Asceneuron is the third spin-off company of Merck Serono, apart from Prexton ...

Merck Serono, a division of Merck, Darmstadt, Germany, announced today the creation of Quartz Bio, the second spin-off company resulting from its Entrepreneur Partnership Program launched in April ...